By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AmextaFinanceAmextaFinance
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
AmextaFinanceAmextaFinance
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
AmextaFinance > Investing > Pfizer Named Top Dividend Stock With Insider Buying And 4.46% Yield
Investing

Pfizer Named Top Dividend Stock With Insider Buying And 4.46% Yield

News Room
Last updated: 2023/05/18 at 4:11 PM
By News Room
Share
4 Min Read
SHARE

In this series, we look through the most recent Dividend Channel ”DividendRank” report, and then we cherry pick only those companies that have experienced insider buying within the past six months. The officers and directors of a company tend to have a unique insider’s view of the business, and presumably the only reason an insider would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both. So when stocks turn up that see insider buying, and are also top ranked, investors are wise to take notice. One such company is Pfizer, which saw buying by Director Scott Gottlieb.

The Top DividendRank‘ed Stocks With Insider Buying »

Back on May 8, Gottlieb invested $77,005.00 into 2,000 shares of PFE, for a cost per share of $38.50. In trading on Thursday, bargain hunters could buy shares of Pfizer and achieve a cost basis 5.9% cheaper than Gottlieb, with shares changing hands as low as $36.22 per share. It should be noted that Gottlieb has collected $0.41/share in dividends since the time of their purchase, so they are currently down 4.9% on their purchase from a total return basis. Pfizer shares are currently trading -1.29% on the day. The chart below shows the one year performance of PFE shares, versus its 200 day moving average:

Looking at the chart above, PFE’s low point in its 52 week range is $36.22 per share, with $54.93 as the 52 week high point — that compares with a last trade of $36.24. By comparison, below is a table showing the prices at which insider buying was recorded over the last six months:

The DividendRank report noted that among the coverage universe, PFE shares displayed both attractive valuation metrics and strong profitability metrics. The report also cited the strong quarterly dividend history at Pfizer Inc, and favorable long-term multi-year growth rates in key fundamental data points.

The report stated, ”Dividend investors approaching investing from a value standpoint are generally most interested in researching the strongest most profitable companies, that also happen to be trading at an attractive valuation. That’s what we aim to find using our proprietary DividendRank formula, which ranks the coverage universe based upon our various criteria for both profitability and valuation, to generate a list of the top most ‘interesting’ stocks, meant for investors as a source of ideas that merit further research.”

The annualized dividend paid by Pfizer is $1.64/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 05/11/2023. Below is a long-term dividend history chart for PFE, which the report stressed as being of key importance. Indeed, studying a company’s past dividend history can be of good help in judging whether the most recent dividend is likely to continue.

Read the full article here

News Room May 18, 2023 May 18, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
China’s J-10 ‘Dragon’ shows teeth in India-Pakistan combat debut

Even before the fog of war had begun to lift, the Chengdu…

Selling of dollar assets signals start of longer-term shift, warn investors

The dumping of US assets in favour of Europe’s resurgent markets signals…

Why travel didn’t bring the world together

Stay informed with free updatesSimply sign up to the Life & Arts…

What the turmoil in Asian currencies tells us

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Pakistan says it launches military retaliation against India

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

- Advertisement -
Ad imageAd image

You Might Also Like

Investing

Why Home Builders Are Bouncing Today—and Why Their Stocks Are Good Buys

By News Room
Investing

This Beaten-Down Industrial Stock Wants to Call America Home. Why It’s Time to Buy.

By News Room
Investing

These 8 Dividend Aristocrats Can Protect Your Portfolio in a Downturn

By News Room
Investing

Some Lenders Benefit From SBA’s Troubled Loan Program

By News Room
Investing

Social Security Is in Turmoil. Should You Lock In Benefits Now?

By News Room
Investing

Hims & Hers Stock Is Due for a Crash Diet. The GLP-1 Surge Is Fading Fast.

By News Room
Investing

Opinion: The stock-market selloff isn’t over yet. Here are 4 reasons why.

By News Room
Investing

With Trump’s tariffs paused, ‘Big Three’ automakers may race to build inventories

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

YOUR EMAIL HAS BEEN CONFIRMED.
THANK YOU!

Welcome Back!

Sign in to your account

Lost your password?